Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase

What your doctor is reading on

APRIL 02, 2020 -- 

Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median survival has also continued to increase, new research shows.

These trends confirm that more widespread use of NAC prior to surgery is not having a negative impact on survival, as some gynecologic oncologists feared, and that the order in which patients receive those treatments does not affect survival for patients with grades IIIC to IV epithelial ovarian cancer, say researchers presenting the new findings.

"Surgery and chemotherapy have been the gold standard for the treatment of newly diagnosed ovarian cancer for many decades with the exception of low-grade, early-stage disease, where you can just do surgery alone," lead author Anne Knisely, MD, New York–Presbyterian Columbia University Irving Medical Center, in New York City, told Medscape Medical News.

"The important take-away is that survival increased [from 2006 through 2016] irrespective of the accelerated adoption of NAC, so we do not think there is a negative impact from the uptake of NAC in advanced ovarian cancer, although we also don't see an acceleration in survival either," she emphasized.